A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.

被引：0
|
作者：
Masuishi, Toshiki
Taniguchi, Hiroya
Hamauchi, Satoshi
Komori, Azusa
Kito, Yosuke
Mitani, Seiichiro
Hasegawa, Hiroko
Narita, Yukiya
Kadowaki, Shigenori
Ura, Takashi
Ando, Masashi
Mori, Keita
Tajika, Masahiro
Yasui, Hirofumi
Muro, Kei
Yamazaki, Kentaro
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan
[2] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[4] Shizuoka Canc Ctr Hosp, Clin Res Ctr, Shizuoka, Japan
[5] Aichi Canc Ctr Hosp, Dept Endoscopy, Nagoya, Aichi 464, Japan
[6] Shizuoka Canc Ctr, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.723
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
723
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A novel antimetabolite: TAS-102 for metastatic colorectal cancer
    Miyamoto, Yuji
    Lenz, Heinz-Josef
    Baba, Hideo
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 355 - 365
  • [32] Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Zhang, Wu
    Suenaga, Mitsukuni
    Schirripa, Marta
    Cao, Shu
    Yang, Dongyun
    Berger, Martin D.
    West, Jordan David
    Ning, Yan
    Wakatsuki, Takeru
    Mashima, Tetsuo
    Okazaki, Satoshi
    Miyamoto, Yuji
    Hanna, Diana L.
    Marmorino, Federica
    Salvatore, Lisa
    Moretto, Roberto
    Borelli, Beatrice
    Barzi, Afsaneh
    Loupakis, Fotios
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiaochen
    Qiu, Huafeng
    Chen, Yunwang
    Wang, Mingxing
    Zhu, Pengfei
    Pan, Shuangyue
    Deng, Yaya
    Yang, Liu
    Chen, Zheling
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
    Fujii, Hironori
    Matsuhashi, Nobuhisa
    Kitahora, Mika
    Takahashi, Takao
    Hirose, Chiemi
    Iihara, Hirotoshi
    Yamada, Yunami
    Watanabe, Daichi
    Ishihara, Takuma
    Suzuki, Akio
    Yoshida, Kazuhiro
    ONCOLOGIST, 2020, 25 (03): : E469 - E476
  • [35] Analysis retrospective from efficacy with TAS-102 in patients with metastatic colorectal cancer refractory: Experience at two hospitals
    Beatriz, Gonzalez-Astorga
    Cebrian Irene, Gonzalez
    Ma Teresa, Delgado Urena
    Veronica, Conde
    Carmen, Sanchez-Toro
    Javier, Garcia-Garcia
    Encarnacion, Gonzalez-Flores
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
  • [37] Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
    Chen, Duke
    Wu, Yu-Shen
    Lin, Huapeng
    Wang, Yihan
    Li, Longhao
    Zhang, Tao
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2915 - 2924
  • [38] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Bendell, Johanna C.
    Rosen, Lee S.
    Mayer, Robert J.
    Goldman, Jonathan W.
    Infante, Jeffrey R.
    Benedetti, Fabio
    Lin, Donghu
    Mizuguchi, Hirokazu
    Zergebel, Christopher
    Patel, Manish R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 925 - 932
  • [39] Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC).
    Grell, Peter
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Tuskova, Helena
    Buchler, Tomas
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] Initial experience of TAS-102 chemotherapy in Australian patients with chemorefractory metastatic colorectal cancer.
    Jalali, Azim
    Wong Hui-Li
    Wong, Rachel
    Lee, Margaret
    Gately, Lucy
    Loft, Matthew
    Shapiro, Jeremy David
    Kosmider, Suzanne
    Tie Jeanne
    Ananda, Sumitra
    Yeung, Justin
    Jennens, Ross
    Lee, Belinda
    McKendrick, Joseph James
    Lim, Lionel
    Khattak, Muhammad Adnan
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345